Andy Szeto

6PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Epidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 19, 2025
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Constantine S Tam, Mary Ann Anderson, Martin Šimkovič

|Dec 08, 2024
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Mazyar Shadman, Talha Munir, Tadeusz Robak

|Jul 14, 2022
The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study.

C Adrian Austin, Andy Szeto, Apoorva Gupta

|Feb 14, 2022
The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents.

Christine E Kistler, Charles Adrian Austin, Junjian J Liu

|Sep 20, 2021
Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.

Andy H Szeto, Tyler Bucci, Allison Deal

|Jun 21, 2021
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Stephanie I Kim, Andy H Szeto, Katherine P Morgan

Pageof 1

Frequent Collaborators

3 joint publications

Daniel J Crona

2 joint publications

Martin Simkovic

2 joint publications

Paolo Ghia

2 joint publications

Ian W Flinn